Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis

Clinical Therapeutics

Volumn 21, Issue 11, 1999, Pages 1924-1936

  Cobos, Albert ^a,d   Jovell, Albert J ^b   García Altés, Anna ^b   García Closas, Reina ^c   Serra Majem, Lluis ^c  

^a Departamento Médico   (Spain)

^b Catalan Agency for Health Technology Assessment and Research   (Spain)

^c UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^d NONE   (Spain)

Author keywords

Cholesterol; Cost effectiveness analysis; Health economics; Modeling

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; SIMVASTATIN;

ALGORITHM; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 0032763738     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)86740-5     Document Type: Note

References (41)

1. 1. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J. 1994;308:367-372.
2. 2. Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol. 1995;76:10C-17C.
3. 3. Levine GN, Keaney JN, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med. 1995;332:512-521.
4. 4. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: A new look at old data. Circulation. 1995;91:2274-2282.
5. 5. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89: 1329-1345.
6. 6. Pyorala K, De Baker G, Graham I, et al, on the behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society, and European Society of Hypertension. Eur Heart J. 1994;15:1300-1331.
7. 7. Sociedad Española de Medicina Interna y Liga para la Lucha contra la Hipertensión Arterial. Recomendaciones para la prevención primaria de la enfermedad cardiovascular. Clin Invest Arterioscler. 1994;6:62-102.
8. 8. Estudio Descriptivo de los Planes de Salud en España (Descriptive study of the Health Plans in Spain). Madrid: Ministerio de Sanidad y Consumo, Dirección General de Alta Inspección y Relaciones Institucionales; 1994.
9. 9. La Declaració de Vitoria Sobre Salut Cardiovascular. Barcelona: Departament de Sanitat i Seguretat Social; 1995.
10. 10. La Declaració de Catalunya: Invertir en Salut Cardiovascular. Barcelona: Departament de Sanitat i Seguretat Social; 1996.
11. 11. De Abajo FJ, Madurga M, Montero D, et al. Trends in the supply and use of lipid-lowering drugs in Spain, 1983 through 1991. Therapie. 1993;48:145-149.
12. 12. IMS. The Pharmaceutical Market, Spain. IMS: Ibérica S.A., Spain; 1997.
13. 13. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol. 1994;73:3D-11D.
14. 14. Martens LL, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: Comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther. 1994;16:1052-1062.
15. 15. Morris S, McGuire A, Caro J, et al. Strategies for the management of hypercholesterolemia: A systematic review of the cost-effectiveness literature. J Health Serv Res Policy. 1997;2:231-250.
16. 16. Jacobson TA. Cost-effectiveness of 3-hydroxy-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era. Am J Cardiol. 1996; 78:32-41.
17. 17. Morris S, McGuire A, Hogan T. The economics of low density lipoprotein cholesterol reduction with fluvastatin sodium. Rev Contemp Pharmacother. 1996;7:191-201.
18. 18. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother. 1995;29: 743-759.
19. 19. Spearman ME, Summers K, Moore V, et al. Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization. Clin Ther. 1997;19:582-599.
20. 20. Kong SX, Gandhi SK, Crawford SY, et al. Pharmacoeconomic evaluation of HMG-CoA reductase inhibitors in the treatment of hypercholesterolemia. Am J Managed Care. 1996;2:1055-1073.
21. a edició). Barcelona: Departament de Sanitat i Seguretat Social. Generalitat de Catalunya; 1996:27-31, 78-80.
22. 22. Clarke R, Frost C, Collins R, et al. Dietary lipids and blood cholesterol: A quantitative meta-analysis of metabolic ward studies. Br Med J. 1997;314:112-117.
23. 23. Rothschild V, Logothetis N. Probability Distributions. New York: John Wiley & Sons; 1986:62-63.
24. 24. Kong SX, Crawford SY, Gandhi SK, et al. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the treatment of patients with hypercholesterolemia: A meta-analysis of clinical trials. Clin Ther. 1997;19:778-797.
25. 25. Delea TE, Hogan TJ, Gasper MC, et al. Cost-effectiveness of cholesterol-lowering drugs: A re-examination of treatment alternatives. Value Health. In press.
26. 26. Simons A, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Allina. 1996;164:208-211.
27. 27. Gisbert R, Brosa M. Base de datos de costes sanitarios (v 1.0) [database on CD-ROM]. Barcelona, Spain: Soikos, 1998.
28. 28. Boletín Mensual de Estadística. Madrid: Instituto Nacional de Estadística; August-September 1997.
29. 29. Indicadores de la Prescripción Farmacéutica en el Sistema Nacional de Salud. Vol. 15, Enero-Junio de 1997. Madrid: Subdirección General de Coordinación Administrativa, Instituto Nacional de Salud; 1997.
30. 30. Regazzi MB, Icona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc. 1993;25:2732-2734.
31. 31. Kantola T, Kivisto KT, Neuvonen PJ. Grape-fruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1998;63:397-402.
32. 32. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998;63:332-341.
33. 33. Nordin C, Dahl ML, Eriksson M, et al. Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism? Lancet. 1997;350:29-30.
34. 34. Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ. 1996;56:1-11.
35. 35. O'Connor PJ, Rush WA, Trence DL. Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization. J Fam Pract. 1997;44:462-467.
36. 36. Fumarga EM. Pharmacist management of a hyperlipidemia clinic. Am J Hosp Pharm. 1993;50:91-95.
37. 37. Kruse W, Schlierf G. Monitoring compliance in clinical trials. Lancet. 1990;335: 803-804.
38. 38. Macià R, Pena A, Marrugat J, et al. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. J Epidemiol Community Health. In press.
39. 39. Illingworth DR, Erkelens DW, Keller U, et al. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin and simvastatin. Lancet. 1994; 343:1554-1555.
40. 40. Masana L, Pedro-Botet J, Roe E, et al. Impacto del consenso para el control de la colesterolemia en España. Med Clin. 1998; 110:598-599.
41. 41. Brotons C, Server M, Pintó X, et al. Impacto del consenso para el control de la colesterolemia en España. Med Clin. 1996; 108:9-15.